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ABSTRACT
Objectives: Anemia, deﬁned as having low levels of hemoglo-
bin (HGB), is caused by disease-related (e.g., bone marrow
suppression, nutritional deﬁciency) or treatment-related (e.g.,
chemotherapy, antiretroviral therapy) factors. Although
epoetin alfa has been shown to improve HGB outcomes in
cancer, HIV/AIDS, and chronic kidney disease (CKD), these
results have been viewed in isolation, rather than across
populations. The purpose of this article is to review ﬁndings
from trials that evaluated the impact of epoetin alfa on HGB
and health-related quality of life (HRQL) across various popu-
lations with different underlying causes of anemia.
Methods: A review of clinical trials published in English
between January 1993 and September 2005. Searches were
conducted using MEDLINE and EMBASE. Between- and
within-group changes in HGB and HRQL were examined.
Results: One hundred ten articles were retrieved and 18 were
reviewed. Statistically signiﬁcant improvements in HGB were
generally seen (1) between groups for cancer patients receiv-
ing epoetin alfa compared with those receiving placebo or
standard of care (SOC) (between-group differences in
changes from baseline to end point ranging from 1.2 to
1.9 g/dl); and (2) within groups for HIV/AIDS and CKD
patients receiving epoetin alfa (changes from baseline to end
point of 2.5 and 2.9 g/dl and 2.7 g/dl, respectively). Statisti-
cally and clinically signiﬁcant improvements in HRQL, par-
ticularly with regard to fatigue, were seen across chronic
conditions based on the Linear Analog Scale Assessment
energy scale; where improvements of at least 8 mm—
considered clinically relevant—were generally seen (1)
between groups for cancer patients receiving epoetin alfa
compared with those receiving placebo or SOC (differences
in changes from baseline to end point from 0.8 to 19.8 mm);
and (2) within groups for HIV/AIDS and CKD patients
receiving epoetin alfa (changes from baseline to end point of
23 and 25 mm and 28 mm, respectively).
Conclusions: Results of published clinical trials suggest that
treatment of anemia associated with cancer, HIV/AIDS and
CKD can have a signiﬁcant impact on HRQL, particularly
fatigue, and that this impact is both statistically and clinically
signiﬁcant.
Keywords: anemia, cancer, chronic disease, epoetin alfa,
health-related quality of life, HIV, kidney disease.
Introduction
Anemia is deﬁned as having low levels of hemoglobin
(HGB) and is present in many disorders including
cancer, chronic kidney disease (CKD), and infection
with the human immunodeﬁciency virus (HIV)/
acquired immune deﬁciency syndrome (AIDS) [1–3].
In these patients, low HGB levels are often resulting
from inadequate production of red blood cells by the
bone marrow and reduced production of erythropoi-
etin by the kidneys [1]. The etiology of anemia in
oncology and HIV infection is often multifactorial in
nature. In oncology, for example, low HGB levels are
subsequent to cancers of the bone marrow (e.g.,
leukemia or multiple myeloma), cancers that have
metastasized to the bone marrow, or chemotherapy;
whereas in HIV infection, low levels are associated
with opportunistic infections, nutritional deﬁciencies
(e.g., iron and folic acid), antiretroviral therapy, and
inﬁltrative diseases of the bone marrow [4]. Patients
with renal insufﬁciency have reduced HGB levels as a
result of decreased production of erythropoietin [3].
The rationale for treating anemia is based on (1) the
negative effects of anemia itself and (2) the association
of anemia with worse prognosis in a variety of condi-
tions [5]. Anemia-associated fatigue, for example, is
reported in the majority of patients with cancer, HIV/
AIDS, and rheumatoid arthritis (RA) [6,7] and has
been shown to have a negative impact on health-
related quality of life (HRQL) [6,8]—a person or
group’s perceived physical, social, and psychological
level of functioning and well-being. In patients with
cancer, HIV/AIDS, and CKD, anemia has been shown
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to impact work ability, physical and emotional well-
being, and sleep [6,9]. Anemia also has been found to
be a strong predictor of poor survival in patients with
various cancers, renal failure and heart failure—even
after controlling for known prognostic factors (i.e.,
age, sex) and comorbidities [10–13].
Treatment guidelines recommend the correction of
low HGB levels to a target of up to 12 g/dl [14] in
cancer-related anemia, 11 g/dl and above in CKD [15],
and 12 g/dl (13 g/dl in men and 12 g/dl in women)
in HIV/AIDS [16]. For anemia of chronic disease
(ACD), treatment of the underlying disease is the
therapeutic approach of choice [5,17]. If this is not
possible or is unsuccessful in reversing the anemia and
concomitant problems, other recommended therapeu-
tic options include transfusions, iron therapy, and
erythropoetic agents such as epoetin alfa [5]. Epoetin
alfa is currently approved for the treatment of anemia
in cancer patients undergoing chemotherapy, patients
with CKD, and HIV positive patients receiving antiret-
roviral therapy. Recommended starting doses depend
on the intended use and range from 50 to 150 units/kg
three times a week (TIW) or 40,000 units once weekly
(QW) to raise HGB levels to 10 to 12 g/dl [18].
Several literature reviews for these disorders (i.e.,
cancer, HIV/AIDS, RA, CKD, and inﬂammatory bowel
disease) have demonstrated the efﬁcacy and effective-
ness of epoetin alfa for the treatment of anemia and its
beneﬁcial impact on HRQL in each of these respective
conditions [19–23]. However, these evaluations did
not examine the HRQL impact of epoetin alfa across
disorders to understand the effect of epoetin alfa on
HRQL in different populations. The purpose of the
article is to review the ﬁndings from trials that evaluate
the impact of epoetin alfa on HGB and HRQL across
various populations with different underlying causes of
anemia.
Methods
A literature search was conducted to identify clinical
trials that assess the HRQL impact of epoetin alfa
treatment in anemia. The search was conducted using
MEDLINE and EMBASE, and included the following
terms: “anemia,” “quality of life,” “outcomes,” “func-
tional status,” “health status,” “epoetin,” “epoetin
alfa,” “erythropoietin,” “EPO,” “r-HuEPO,” “Pro-
crit,” “erythropoietin recombinant,” “recombinant
human erythropoietin,” “human recombinant erythro-
poietin,” “rhuepo,” “r-hepo,” “Eprex,” “Epogen,”
“Erypo,” “Epopen,” “Epoxitin,” and “Globuren.”
Articles were limited to those conducted in humans
and published in the English language from January
1993 and September 2005. Reference lists of identiﬁed
articles were reviewed for other articles on HRQL,
epoetin alfa, and anemia.
One hundred ten articles were identiﬁed (see Fig. 1).
Abstracts in the following areas were excluded from
retrieval and review: 1) review articles; 2) letters to the
editor; 3) reports of previously published data; or
4) efﬁcacy trials that did not evaluate HRQL. Studies
of CKD patients receiving dialysis were outside the
scope of this review. This left 34 articles for further
review.
Because there were many studies that assessed the
HRQL impact of epoetin alfa in anemic cancer
patients (n = 72), only publications that evaluated data
from randomized controlled trials (RCTs) were used in
that section of our review. Of the 25 cancer publica-
tions using data from RCTs, 11 reported ﬁndings from
the same clinical trial and were excluded so that results
of these trials were not over-represented in the analysis
[24–32]. In these situations, only data from the
primary study publication are presented [29,32]. Data
from subsample analyses, where population character-
Articles of non-RCT 
design were not 
included in review for
cancer 
   25 Cancer RCT 
articles retrievedArticles reporting findings 
from the same trial were 
not included in review for 
cancer
Articles that did not provide 
data values were not
included in review for
caner 
110 Abstracts reviewed
72 Cancer
abstracts reviewed
9 HIV/AIDS or CKD 
articles retrieved
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articles reviewed
9 HIV/AIDS or CKD 
 articles reviewed
18 Articles reviewed
9 HIV/AIDS or CKD 
abstracts reviewed 
Figure 1 A diagram of the 110 abstracts
reviewed. CKD, chronic kidney disease; RCT,
randomized controlled trial.
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istics were different from the primary publication
study, are presented to gain insight into potential dif-
ferential effects across these populations [25,30]. Five
publications were excluded because they did not
provide numeric values for HRQL data or report ﬁnd-
ings for between-group differences for epoetin alfa and
comparator(s) [33–37].
Because there were few studies that assessed the
HRQL impact of epoetin alfa in anemic HIV or CKD
patients (n = 9), all publications that evaluated data
from clinical trials were used in that section of our
review.
Findings are presented by disease area and include
descriptions of 1) the types of trials conducted; 2) the
mean change scores between groups (e.g., epoetin alfa
vs. placebo) and across time points (e.g., baseline to
week 8) for selected instruments; and 3) changes in
selected clinical measures across time points (e.g.,
HGB, percent of patients requiring a transfusion).
Tables are provided to summarize the data. However,
limitations in data availability limited our ability to
report all ﬁndings consistently, particularly for the
CKD trials.
Results
Health-Related Quality of Life Associated with Epoetin
Alfa in Cancer
Summary of RCTs of epoetin alfa that evaluate
HRQL in cancer. Of the nine studies reviewed
(Table 1), seven evaluated anemia of solid malignancy,
with three studies evaluating breast cancer patients
exclusively [25,29,30,32,38–42]. Seven of nine trials
were at least 28 weeks long and compared epoetin alfa
as a single agent to placebo (n = 6) or standard of care
(SOC) (n = 3); with epoetin alfa doses ranging from
10,000 to 20,000 subcutaneously (sc) TIW (based on
150–300 U/kg) to 40,000 sc QW [25,29,30,32,38–
42]. In general, studies evaluated equal numbers of
middle-aged men and women (except breast cancer-
speciﬁc studies, where almost 100% were women).
Mean baseline HGB levels were comparable between
epoetin alfa and placebo/SOC groups within each
study, ranging from 9.5 to 12.8 g/dl and 9.4 to 13.0 g/
dl, respectively.
All studies used at least one of the Functional
Assessment of Cancer Therapy (FACT) measures and
seven used the Linear Analog Scale Assessment
(LASA), evaluating between-group differences for
changes in HRQL from baseline to end point (e.g., last
value, 12 weeks, etc.). The FACT-Anemia (FACT-An)
is a 47-item, self-administered questionnaire designed
to measure anemia-related HRQL (20 items; FACT-An
anemia subscale) and general HRQL (27 items;
FACT-G total) in cancer patients [43]. The FACT-An
anemia subscale consists of 13 fatigue-associated items
(i.e., FACT-An fatigue subscale) and seven nonfatigue
associated items. Speciﬁc items in the FACT-An anemia
and FACT-An fatigue subscales measure the impact of
illness on fatigue, energy level, and ability to do usual
activities. For each of the FACT measures, higher
scores indicate better HRQL, with FACT-An anemia
subscale scores ranging from 0 to 80 and FACT-An
fatigue subscale scores ranging from 0 to 52. The
FACT scales have been validated in cancer [43–46].
Work by Cella and colleagues suggests that changes
or differences of 3 points in the FACT-An fatigue sub-
scale is clinically signiﬁcant in patients with cancer [47].
Estimates of clinically signiﬁcant changes or differences
are not available for the FACT-An anemia scale [47].
The LASA (also known as the Cancer Linear
Analog Scale [CLAS]) consists of three visual analog
scales (VAS) that measure energy level, ability to do
daily activities, and overall quality of life. Scores for
the LASA represent the distance in millimeters
(100-mm scales) between the left extreme of the scale
and the patient’s mark on the line. The left extreme
represents the worst possible level for each of the con-
cepts and the right extreme represents the best possible
level. The LASA scales have been used in several cancer
trials [44,46–48]. The LASA for overall quality of life
has shown to be reliable and valid in this population
[49]. Changes in LASA scores of 8 to 10 mm are
considered clinically relevant [50,51] based on previ-
ous research (Norman et al., 2003) [52], which suggest
that a change of 1/2 of the baseline standard deviation
(SD) of any HRQL instrument may be considered
clinically signiﬁcant change.
Summary of clinical ﬁndings in cancer from RCTs. In
trials reporting HGB changes for patients receiving
epoetin alfa compared with placebo/SOC (Table 2),
absolute differences in HGB were noted in all studies
and statistically signiﬁcant hematologic improvements
were seen in 4 of 8 studies. Studies of solid or nonmy-
eloid hematologic cancer patients with anemia demon-
strated signiﬁcant absolute between-group differences
in mean HGB changes from baseline to end point
ranging from 1.4 to 1.9 g/dl (all P < 0.001)
[29,32,40,42]. With the exception of one study where
the between-group difference in HGB was 2.9 g/d [41],
similar absolute differences were seen in anemic
patients with breast cancer and nonmyeloid hemato-
logic malignancy, although statistical signiﬁcance was
not reached [25–30,38].
The percentage of patients requiring a transfusion
during a trial was signiﬁcantly lower for those receiv-
ing epoetin alfa compared with placebo/SOC, ranging
from 9% to 36% for those receiving epoetin alfa
and 23% to 65% for those receiving placebo/SOC
(most P < 0.02) [29,32,39,40,42]. With the exception
of one study in patients with solid or nonmyeloid
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Table 1 Summary of randomized controlled trials of epoetin alfa that evaluate HRQL in cancer
Citation Population Design and methods QOL measures QOL evaluation
Bajetta et al., 2004*
[25]
• Breast CA patients for
which nonplatinum
CT was underway or
imminent
• n = 114
• Mean age in years:
—Epoetin a: 55
—Placeco: 53
• % Female:
—Epoetin a: 99
—Placebo: 100
• Mean baseline HGB in g/dl
(SD):
—Epoetin a: 10.0 (1.6)
—Placebo: 9.9 (1.0)
• RCT, double-blind,
multicenter
• Duration: 28 weeks
• Treatment:
—Epoetin a: 150 U/kg sc
TIW
—Placebo sc TIW
• FACT-An
• FACT-G
• FACT-An fatigue
• LASA
• Between-group
change in HRQL from
baseline to last value
Casadevall et al., 2004
[38]
• Myelodysplastic syndromes
• n = 60
• Mean age in years (range):
—Arm A (Epoetin a
+G-CSF): 73 (43–80)
—Arm B (supportive care):
71 (48–89)
• % Female:
Arm A: 53
Arm B: 47
• Mean baseline HGB in g/dl
(SEM):
—Arm A = 8.6 (1.2)
—Arm B = 8.6 (1.1)
• RCT, open-label, multicenter
• Duration: 52 weeks
• Treatment:
—Epoetin a (20,000 U) and
G-CSF (105 mg) given TIW
for 12 weeks. Responders
were given Epoetin a
alone for another
40 weeks.
—Supportive care for
52 weeks
• FACT-An
• FACT-An fatigue
• FACT-An anemia
• Between-group
differences: change in
HRQL from baseline to
weeks 12, 18 and 52
Chang et al., 2005
[39]
• Breast CA patients receiving
CT
• n = 354
• Mean age in years (SD):
—Epoetin a: 54 (11)
—Standard of care: 50 (10)
• % Female:
—Epoetin a: 100
—Standard of care: 100
• Mean baseline HGB in g/L
(SEM):
—Epoetin a: 11.2 (0.9)
—Standard of care: 11.3
(0.8)
• RCT, open-label, multicenter
• Duration: 28 weeks
• Treatment:
—Epoetin a: 40,000 U QW
—Standard of care
• FACT-An anemia
• LASA
• Between-group differences:
change in HRQL from
baseline to week 12 and
end of study (range
16–28 weeks)
Iconomou et al., 2003
[40]
• CA patients with solid
malignancy
receiving CT
• n = 122
• Mean age in years (SD):
• Epoetin a: 61 (11)
• Control: 62 (10)
• % Female:
—Epoetin a: 61
—Untreated control: 56
• Mean baseline HGB in g/dl
(SD):
—Epoetin a: 10.1 (0.6)
—Control: 10.1 (0.4)
• RCT, single-center
• Duration: 12 weeks
• Treatment:
• Epoetin a: 10,000 U TIW
for 12 weeks
• Control: untreated
• All patients received 200 mg
oral elemental iron daily
• FACT-An
• LASA
• Between-group differences:
change in HRQL from
baseline to weeks
4 and 12
Littlewood et al., 2001*
[29]
• Solid or nonmyeloid
hematologic malignancy
patients for which
nonplatinum CT was
underway or imminent
• n = 375
• Mean age in years (SD):
• Epoetin a: 58 (14)
• Placebo: 60 (14)
• % Female:
—Epoetin a: 66
—Placebo: 69
• Mean baseline HGB in g/dl
(SD):
—Epoetin a: 9.9 (1.1)
—Placebo: 9.7 (1.1)
• RCT, double-blind,
multicenter
• Duration: 28 weeks
• Treatment 2:1 ratio:
—Epoetin a: 150–300 U/kg
TIW
—Placebo
• FACT-G
• FACT-An fatigue
• FACT-An anemia
• LASA
• SF-36
• Between-group
differences: change in HRQL
from baseline to week 16
and last value
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hematologic cancers [29], survival rates were not sig-
niﬁcantly different between epoetin alfa and placebo/
SOC groups [32,42].
Summary of HRQL ﬁndings in cancer from RCTs.
Table 3 shows the pattern of effects of epoetin alfa on
HRQL in RCTs of patients with various cancers. In a
study of 375 solid or nonmyeloid hemaloglogic cancer
patients receiving nonplatinum chemotherapy, statisti-
cally signiﬁcant improvement in the FACT-An fatigue
score from baseline to last assessment (up to 28 weeks)
was seen for epoetin alfa compared with placebo (3.0
and -2.2, respectively; P = 0.004) [29]. Similar ﬁnd-
ings were seen in studies evaluating anemic women
Table 1 continued
Citation Population Design and methods QOL measures QOL evaluation
Littlewood et al., 2003*
[30]
• Nonmyeloid hematologic
malignancy patients for
which nonplatinum
CT was underway or
imminent
• n = 173
• Mean age in years (SD):
—Epoetin a: 59
—Placebo: 64
• % Female:
—Epoetin a: 49
—Placebo: 45
• Mean baseline HGB in g/dl
(SD):
—Epoetin a: 9.9 (1.2)
—Placebo: 9.7 (1.2)
• RCT, double-blind,
multicenter
• Duration: 28 weeks
• Treatment 2:1 ratio:
• Epoetin a: 150–300 U/kg
TIW
• Placebo
• FACT-G
• FACT-An fatigue
• FACT-An
• LASA
• Between-group
differences: change in
HRQL from baseline to
week 16 and last value
O’Shaughnessy
et al., 2005 [41]
• Breast CA patients treated
with CT
• n = 94
• Mean age in years (SD):
—Epoetin a: 53 (10)
—Placebo: 54 (12)
• % Female:
—Epoetin a: 100
—Placebo: 100
• Mean baseline HGB in g/dl
(SD):
—Epoetin a: 12.8 (1.0)
—Placebo: 13.0 (1.0)
• RCT, double-blind, pilot
• Duration: 12 weeks with
6 months follow-up
• Treatment:
—Epoetin a: 40,000 sc
QW for 12 weeks
—Placebo
• FACT-An anemia
• Karnofsky PS
• LASA
• Between-group
differences:
—change in HRQL from
baseline to 1 week before
cycle 4 and at 6 months.
—change in HRQL from
baseline to before each
treatment cycle and at
6 months
Savonije et al., 2005
[42]
• Solid malignancy patients
planning to receive 2–6
more cycles of
platinum-based CT
• n = 313
• Mean age in years (SD):
—Epoetin a: 57 (11)
—BSC: 58 (10)
• % Female:
—Epoetin a: 45
—BSC: 41
• Mean baseline HGB in g/dl
(SD):
—Epoetin a: 10.7 (1.0)
—BSC: 10.8 (1.0)
• RCT, open-label, multicenter
• Duration: 4 weeks after last
CT with 12 months
follow-up
• Treatment 2:1 ratio:
—Epoetin a: 10,000 IU sc
TIW until 4 weeks after
last CT
—BSC
• FACT-G
• FACT-An anemia
• FACT-An fatigue
• FACT-An
Nonfatigue
• LASA
• Between-group
differences: change in
HRQL from baseline to
last value
Witzig et al., 2005
[32]
• Incurable CA patients
receiving
myelosuppressive CT
• n = 344
• Mean age in years (SD):
—Epoetin a: 64 (12)
—Placebo: 64 (13)
• % Female:
—Epoetin a: 55
—Placebo: 57
• Mean baseline HGB in g/dl
(median):
—Epoetin a: 9.5 (9.6)
—Placebo: 9.4 (9.5)
• RCT, double-blind
• Duration: 16 weeks
• Treatment 2:1 ratio:
—Epoetin a: 40,000 U sc
QW
—Placebo
• Uniscale
• SDS
• FACT-An
• FACT-G
• FACT-An fatigue
• Between-group
differences: change in
HRQL from baseline to
last value
*Researchers used data from the same clinical trial, referred to as the Epoetin Alfa Study Group.
BID, twice a day; BSC, best supportive care; CA, cancer; CLAS, Cancer Linear Analog Scale (also known as the Linear Analog Scale Assessment [LASA]); CT, Chemotherapy;
FACT-An, Functional Assessment of Cancer Therapy-Anemia; FACT-G, Functional Assessment of Cancer Therapy-General; G-CSF, Granulocyte Colony Stimulating Factor; HCT,
hematocrit; HGB, hemoglobin; HRQL, health-related quality of life; IU, international units; KG, kilograms; LASA, Linear Analog Scale Assessment (also known as the Cancer Linear
Analog Scale [CLAS]); MID, Minimally Important Difference; NA, not available; QOL, quality of life; QW, every week; RCT, randomized controlled trial; RT, radiotherapy; sc,
subcutaneously; SD, standard deviation; SDS, Symptom Distress Scale;TIW, three times a week; U, units.
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with breast cancer (n = 338) [39] and solid malignancy
patients receiving chemotherapy (n = 112 and 221,
respectively) [40,42], where 5-point absolute differ-
ences from baseline to end point were seen between
epoetin alfa and placebo groups (all P < 0.05). Addi-
tional studies in anemic patients with breast cancer,
myelodysplastic syndromes, and nonmyeloid hemato-
logic malignancy also approximated 5-point absolute
between-group differences in FACT-An fatigue scores
(range 1.8–7.9 points) [25,30,38]. Sample sizes were
small for some of the studies and did not reach statis-
tical signiﬁcance (n range 35–135) [25,38].
Similar ﬁndings were observed for the FACT-An
anemia subscale when used in the same studies of solid
and nonmyeloid cancers, including breast cancer
[29,39], which showed a 6.6-point absolute between-
group difference favoring epoetin alfa (P < 0.007 and
P < 0.0001, respectively). In patients with solid malig-
nancy, the FACT-An anemia showed a 5.8-point abso-
lute difference (P = 0.01) [42]. Additional studies in
patients with breast cancer or myelodysplastic syn-
dromes approximated a 3-point absolute difference
in FACT-An anemia scores (range 2.1–8.1 points)
[38,41]. Again, sample sizes were small for some of the
studies and did not reach statistical signiﬁcance (n
range 35–67) [38,41].
Positive HRQL ﬁndings were seen for epoetin alfa
based on the three LASA scales (i.e., energy, daily
activities, and overall HRQL), where absolute
between-group differences of at least 8 points were
seen in six of the seven studies favoring epoetin alfa
over placebo or SOC (Table 4). In four of the eight
studies evaluating solid malignancy or nonmyeloid
hematologic malignancy receiving chemotherapy
[29,39,40,42], signiﬁcant improvements were seen in
LASA energy scores from baseline to last assessment
for epoetin alfa compared with placebo (range 3.3–
8.1 mm for epoetin alfa vs. -6.9 to -1.4 mm for
placebo/SOC; all P < 0.05). Similar results were seen
in the daily activities and overall LASA scales (all
P < 0.03). Additional studies also approximated
8 mm absolute between-group differences in LASA
scale scores (range 0.8–19.8 mm) [25,30,41].
Signiﬁcance tests were not reported for these
evaluations.
Health-Related Quality of Life Associated with Epoetin
Alfa in HIV/AIDS
Summary of trials of epoetin alfa that evaluate
HRQL in HIV/AIDS. Of the six trials evaluating the
effect of epoetin alfa on HRQL in anemic patients with
HIV (Table 5), three were RCTs comparing changes in
HGB between epoetin alfa- and placebo-treated
groups from baseline to end point [53–55] and three
were open-label, single-arm studies testing within-
group differences from baseline to end point [56–58]. Ta
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Four of the six trials were 16 weeks long (12–
24 weeks). Epoetin alfa doses ranged from 4,000 U sc
every day (QD) to 40,000 to 60,000 U sc QW. Most
patients were male (66% or more of the study popu-
lation) with a mean age of 41 years (38–44 years). For
RCTs, mean baseline HGB levels were comparable
between epoetin alfa and placebo/SOC groups (11.1
vs. 11.5, respectively) and epoetin alfa ﬁxed and
weight-based dosing groups (10.6 vs. 10.5, respec-
tively) [53,55]. Slightly lower baseline HGB levels were
seen in the single-arm studies (9.6 and 9.7 g/dl)
[56,58].
Table 5 Summary of epoetin alfa trials that evaluate HRQL in HIV/AIDS
Citation Population Design and methods HRQL measures HRQL evaluation
Abrams et al., 2000
[56]
• HIV-positive anemic patients
• n = 221
• Mean age in years: 41
• % Female: 21
• Mean baseline HGB in g/dl:
9.6
• Nonrandomized, open-label
• Duration: 16 weeks
• Treatment:
—Epoetin a: 100–300 U/kg
sc TIW
• FAHI • Within-group differences:
change in HRQL from
baseline to last value
Grossman et al.,
2003 [53]
• HIV-positive anemic patients
receiving stable antiretroviral
therapy
• n = 272
• Mean age in years (SD):
—Epoetin a QW: 44 (9)
—Epoetin a TIW: 43 (9)
• % Female:
—Epoetin a QW: 28
—Epoetin a TIW: 31
• Mean baseline HGB in g/dl
(SD):
—Epoetin a QW: 10.6 (1.2)
—Epoetin a TIW: 10.5 (1.1)
• RCT, open-label, multicenter
• Duration: 16 weeks
• Treatment:
—Epoetin a: 40,000–
60,000 U sc QW
—Epoetin a: 100–300 U/kg
sc TIW
• LASA
• MOS-HIV
—PCS
—MCS
• Between-group differences:
change in HRQL from
baseline to weeks 8 and 16
and last value
• Within-group differences:
change in HRQL from
baseline to weeks 8
and 16 and last value
Henry et al., 1992
[54]
• Anemic patients with AIDS
receiving zidovudine therapy
• n = 255
• Mean age in years (range):
—Epoetin a: 38 (24–64)
—Placebo: 41 (24–64)
• % Female:
—Epoetin a: 2
—Placebo: 5
• Mean baseline HCT%: 26.8
• RCT, double-blind,
multicenter
• Duration: 12 weeks
• Treatment:
—Epoetin a: 100–200 U/kg
IV or sc TIW
—Placebo
• LASA • Between-group differences:
change in HRQL from
baseline to end of study
Revicki et al., 1994*
[57]
• Anemic patients with AIDS
• n = 251
• Mean Age in Years (SE): 38
(0.5)
• % Female: 6
• Mean baseline HCT
percentage
(SE): 27.9 (0.3)
• Open-label, multicenter
• Duration: 24 weeks
• Treatment:
—Epoetin a: 4000 U sc QD
• SF-36
• SIP subscales
—Home
management
—Sleep and rest
—Alertness behavior
—Social interaction
• QAL
—Life satisfaction
—Health satisfaction
• Within-group differences:
change in HRQL from
baseline to weeks 12 and 24
Saag et al., 2004
[58]
HIV-positive anemic patients
receiving antiretroviral therapy
• n = 650
• Mean age in years (SD): 43
(9)
• % Female: 34
• Mean baseline HGB in g/dl
(SD): 9.7 (1.1)
• Open-label, multicenter
• Duration: 16 weeks
• Treatment:
—Epoetin a: 40,000–
60,000 U sc QW
• LASA
• MOS-HIV
• Within-group differences:
change in HRQL from
baseline to weeks 8
and 16 and last value
Sulkowski et al., 2005
[55]
Anemic patients with HIV/
HCV coinfection receiving
IFN/RBV therapy
• n = 66
• Mean age in years (SE): NR
• % Female: NR
• Mean baseline HGB in g/dl
(SE):
—Epoetin a: 11.1 (0.3)
—SOC: 11.5 (0.3)
• RCT, open-label, multicenter
• Duration: 16 weeks
• Treatment:
—Epoetin a: 40,000–
60,000 U sc QW
—SOC
• Modiﬁed SF-12
(acute)
—PCS
—MCS
• Between-group
differences: change in HRQL
from baseline to 16-weeks
*HQL study was a subgroup study within a larger study.
AIDS, Acquired Immunodeﬁciency Syndrome or Acquired Immune Deﬁciency Syndrome; FAHI, Functional Assessment of Human Immunodeﬁciency Virus Infection; HCT,
hematocrit; HGB, hemoglobin; HIV, human immunodeﬁciency virus; HRQL, health-related quality of life; IFN/RBV, interferon/ribavirin; IU, international units; KG, kilograms; LASA,
Linear Analog Scale Assessment; MCS, mental component score; MOS-HIV, Medical Outcomes Study HIV Health Survey; NA, not available; NR, not reported; PCS, physical
component score;QAL,Quality of American Life;QW, every week; RCT, randomized controlled trial; sc, subcutaneously; SD, standard deviation; SOC, standard of care;TIW, three
times a week; U, units.
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Four of the six studies used Medical Outcomes
Study (MOS)-derived scales: three (MOS-HIV or
SF-36) and one modiﬁed SF-12 to assess HRQL
[53,55,57,58]. The LASA scales were used in three of
the studies [51,52,56]. The MOS-HIV is a 35-item, self
administered HRQL questionnaire that measures 10
dimensions of health as well as one item evaluating
health transition in HIV-infected patients: overall
health, physical function, role function, social func-
tion, cognitive function, pain, mental health, energy/
fatigue, health distress, and quality of life. Scale scores
range from 0 to 100, with high scores representing
better HRQL. Two overall summary scores, the physi-
cal component summary score (PCS) and the mental
component summary score (MCS), can also be
obtained. PCS and MCS scores are transformed to
have a mean of 50 and standard deviation of 10;
higher scores indicate better HRQL. The MOS-HIV
measure had been validated in patients with HIV
[59–61]. Changes or differences of 2 to 3 points in the
PCS and MCS scores are considered clinically relevant
[60–62].
Summary of clinical ﬁndings in trials for HIV/
AIDS. Clinical improvements were seen over time for
patients receiving epoetin alfa (Table 6). Two of the six
studies showed signiﬁcant differences in mean HGB
changes from baseline to end point (up to 16 weeks) of
2.5 and 2.9 g/dl [53,58].
Summary of HRQL ﬁndings in trials for HIV/
AIDS. Based on the MOS-HIV, HRQL improvements
for patients receiving epoetin alfa were generally seen
by week 8 and maintained until the end of the study
(Table 7). In two studies of HIV-positive anemic
patients receiving antiretroviral therapy (n = 272 and
650, respectively), signiﬁcant improvements were seen
for all 10 domains from baseline to last assessment (up
Table 6 Summary of clinical ﬁndings in HIV/AIDS from trials of epoetin alfa
Citation Time frame
Clinical measures
Mean change in HGB (g/dl)† % Requiring transfusion
Grossman et al., 2003‡§ [53] Baseline to week 16 2.9* (n = 142) 2.1 (n = 142)
Saag et al., 2004¶ [58] Baseline to week 8 2.7* (n = 522) —
Baseline to week 16 2.8* (n = 384) —
Baseline to last assessment 2.5* (n = 632) —
*P < 0.0001.
†P-value for within-group differences between baseline and week 8, week 16, or ﬁnal change scores for patients receiving epoetin a.
‡Data for QW dosing (similar ﬁndings observed for TIW dosing).
§No signiﬁcant differences between QW and TIW dosing groups for ﬁnal change scores.
¶Efﬁcacy population.
HGB, hemoglobin.
Table 7 Summary of HRQL ﬁndings in HIV/AIDS from trials of epoetin alfa using the MOS-HIV scales
MOS scales
Mean change scores from baseline for MOS-HIV scales1
Grossman et al., 20032 Revicki et al., 19943 Saag et al., 2004
8-week
change
(n = 105–121)
16-week
change
(n = 98–107)
Final
change4,5
(n = 117–127)
12-week
change
(n = 153)
24-week
change
(n = 93)
8-week
change
(n = 473–509)
16-week
change
(n = 433–465)
Final
change5
(n = 526–552)
Overall health 11‡ 12¶ 11§ — — 9.1† 12.0§ 10.8§
Physical function 13‡ 16¶ 16§ 5.1 7.7 11.5† 15.0§ 13.6§
Role function 14‡ 19¶ 18§ –2.4* 5.4 5.3† 11.5§ 9.9§
Social function 11‡ 11¶ 10† — — 11.0† 13.7§ 12.7§
Cognitive function 4 6¶ 4*6 — — 5.4† 7.7§ 7.0§
Pain 5 3¶ 5*6 — — 6.6† 8.5§ 8.0§
Mental health 5‡ 7¶ 6† — — 6.5† 8.2§ 7.8§
Energy/fatigue 18† 20¶ 18§ 6.2* 10.2* 14.5† 18.2§ 16.8§
Health distress 9‡ 10¶ 9‡ 3.1 9.4* 10.7† 13.0§ 11.9§
Quality of life 13‡ 13¶ 12§ — — 9.1† 11.7§ 10.7§
Health transition 15‡ 12¶ 11‡ — — 12.6† 12.7§ 12.2§
Mental summary 5‡ 6¶ 5§ — — 5.1¶ 6.4¶ 6.0§
Physical summary 6‡ 7¶ 7§ — — 4.7¶ 6.3¶ 5.7§
*P < 0.05; †P < 0.002; ‡P < 0.001; §P < 0.0001; ¶Not reported.
1P-value for within-group differences between baseline and week 8,week 16,or ﬁnal change scores for patients receiving epoetin a; 2Data for QW dosing (similar ﬁndings observed
forTIW dosing); 3Calculated change scores from data provided at each timepoint for all subjects; 4No signiﬁcant differences between QW andTIW dosing groups for ﬁnal change
scores; 5Last observation carried forward; 6Not signiﬁcant based on Bonferroni procedure experimental type 1 error rate of P < 0.0083.
MOS-HIV PCS and MCS mean = 50; minimally important difference = 2–3 points.
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to 16 weeks) (all P < 0.05) [53,58]. The largest
changes were seen for the physical function (range
11.5–16 points) and energy/fatigue scales (range
14.5–18 points). Changes in PCS and MCS scores
from baseline to last assessment also were statistically
and clinically signiﬁcant in both studies, with differ-
ences ranging from 5 to 7 points [53,58]. In addition,
a study of 251 AIDS patients with anemia demon-
strated signiﬁcant improvements in energy/fatigue at
weeks 12 and 24 (6.2 and 10.2 points, respectively;
P < 0.05) and in health distress at week 24 (9.4 points;
P < 0.05) [57].
Positive HRQL ﬁndings were also seen for epoetin
alfa based on the three LASA scales (i.e., energy, daily
activities, and overall HRQL), where within-group dif-
ferences of approximately 20 mm were generally seen
between baseline and end point in each of the three
studies in which the measure was used (Table 8). In the
studies by Grossman and Saag [53,58], signiﬁcant
improvements were seen in LASA energy scores from
baseline to last assessment (up to 16 weeks) (25 and
23 mm, respectively; P < 0.0001). Similar ﬁndings were
seen in the daily activities and overall LASA scales
(P < 0.0001). A study that reported results for AIDS
patients with low endogenous erythropoietin levels
(500 IU/L), did not demonstrate large improvements;
with changes from baseline to end point ranging from
0.9 to 3.1 mm for the LASA scales [54].
In an RCT in anemic patients with HIV/hepatitis C
virus coinfection, the only RCT identiﬁed that com-
pared the HRQL impact of epoetin alfa to SOC
(n = 66), there were no signiﬁcant differences between
groups in mean SF-12 PCS and MCS change scores
from baseline to week 12 [55]. However, SF-12 PCS
scores from baseline to week 16 were improved signiﬁ-
cantly in patients receiving epoetin alfa (6.0 points;
P = 0.004), whereas no changewas observed in patients
receiving SOC (2.2 points; P = 0.09). Changes in MCS
scores were not signiﬁcant for either the epoetin alfa or
SOC group (2.3 and 0.1 points, respectively).
Health-Related Quality of Life Associated with Epoetin
Alfa in Predialysis CKD
Summary of trials of epoetin alfa that evaluate
HRQL in predialysis CKD. Of the three studies evalu-
ating HRQL changes with epoetin alfa treatment in
patients with predialysis CKD reviewed (Table 9), only
one RCT evaluated between-group differences in mean
changes in HRQL from baseline to end point [63].
Another RCT evaluated between-group differences in
the number of patients experiencing HRQL changes
from baseline to end point [64]; and a nonrandomized
trial compared within-group differences for changes in
HRQL from baseline to end point [65]. In these
studies, epoetin alfa doses were administered either
TIW, with doses ranging from 50 to 150 U/kg TIW or
QW, with doses starting at 10,000 U sc QW and
increasing to 20,000 U sc QW at week 5. Over half of
the patients were female in two of the three studies
[63,65]. Mean baseline HGB levels ranged between 9.1
and 9.7 g/dl [64,65] and mean hematocrit (HCT) per-
centages were 26.8 [63].
Eight different measures were used to assess HRQL
in predialysis CKD patients, including the LASA, MOS
scales, Kidney Disease Questionnaire (KDQ), Sickness
Impact Proﬁle (SIP), and Quality of American Life
Survey (QAL). Several of these scales (e.g., MOS
scales, SIP) are validated generic health status mea-
sures that have been used in various patient popula-
tions, including CKD with anemia [66–74], whereas
the KDQ is a disease-speciﬁc measure that has been
validated in end-stage renal disease patients receiving
epoetin alfa [70].
Summary of clinical ﬁndings trials of predialysis
CKD. Clinical improvements were seen over time in
patients receiving epoetin alfa (Table 10); with signiﬁ-
cant between-group differences [63,65] and within-
group change [65] in mean HGB and HCT levels from
baseline to end point being reported. An RCT of 83
Table 8 Summary of HRQL ﬁndings in HIV/AIDS trials of epoetin alfa using the LASA
Citation Time frame
Mean change scores from baseline for LASA measures1
LASA
Energy
LASA
Daily activities
LASA
Overall
Grossman et al., 20032
[53]
Baseline to Week 8 23* (n = 124) 21* (n = 124) 18* (n = 124)
Baseline to week 16 26† (n = 107) 22† (n = 107) 20† (n = 107)
Baseline to last assessment3,4 25* (n = 126) 21* (n = 126) 19* (n = 126)
Henry et al., 1992 [54] Baseline to last assessment5,6 3.1 (n = 83) 2.0 (n = 83) 0.9 (n = 83)
Saag et al., 2004 [58] Baseline to Week 8 20.7† (n = 503) 17.3† (n = 501) 16.6† (n = 502)
Baseline to week 16 25.3* (n = 455) 21.9* (n = 454) 20.4* (n = 456)
Baseline to last assessment4 23.2* (n = 550) 20.4* (n = 548) 19.3* (n = 549)
*P < 0.0001; †Not reported.
1P-value for within-group differences between baseline and week 8, week 16, or ﬁnal change scores for patients receiving epoetin alfa; 2Data for QW dosing (similar ﬁndings
observed forTIW dosing); 3No signiﬁcant differences between QW andTIW dosing groups for ﬁnal change scores; 4Last observation carried forward; 5Analysis for patients with
low endogenous erythropoietin levels 500 IU/L; 6No signiﬁcant differences between placebo and epoetin a groups for any LASA scale.
HRQL, health-related quality of life; LASA, Linear Analog Scale Assessment (also known as the Cancer Linear Analog Scale [CLAS]); LASA range = 0–100 mm;minimally important
difference = 8–10 mm.
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predialysis CKD patients with anemia showed a mean
increase of 4.7% for those receiving epoetin alfa com-
pared with a decrease of 1.0% for the untreated
control group (P < 0.0001) [63]; whereas a study of
117 predialysis patients showed signiﬁcant differences
in the percentage of epoetin alfa patients with an
increase of at least 6% over baseline (90% for epoetin
alfa 150 U/kg, 79% for 100 epoetin alfa U/kg, 57%
for 50 epoetin alfa U/kg, and 10% for placebo; com-
bined treatment group vs. placebo P < 0.05) [64]. A
large, prospective, open-label trial with 1557 predialy-
sis patients showed a signiﬁcant within-group increase
of 8.6% from baseline to end point, up to 16 weeks,
for patients receiving epoetin alfa (P < 0.0001) [65].
Summary of HRQL ﬁndings in predialysis CKD. In
general, ﬁndings from these studies showed improve-
ments in energy level for anemic predialysis CKD
patients receiving epoetin alfa (Table 10). In the RCT
by Revicki and colleagues, signiﬁcantly better changes
in MOS energy and physical function scores from
baseline to week 48 were seen for epoetin alfa com-
pared with untreated control (5.8 vs. -3.1; P = 0.036
and 7.8 vs. -4.8; P = 0.006, respectively). There were
no other signiﬁcant differences in MOS, SIP, QAL, and
Center for Epidemiologic Studies Depression Scale
(CESD) change scores from baseline to week 48
between epoetin alfa and untreated control. In another
RCT, improvement in work capacity was signiﬁcantly
greater at 8 weeks for those treated with 150 U/kg of
epoetin alfa compared with placebo (both n = 17;
P < 0.05) [64].
In the epoetin alfa trial with 1557 anemic predialy-
sis CKD patients, all LASA quality of life parameters
improved signiﬁcantly from baseline to last evaluable
visit, up to 16 weeks (mean change in mm: 27.9 for
energy, 24.5 for activity, and 22.6 for overall qualify of
life; all P < 0.0001). In addition, all ﬁve KDQ domains
(i.e., physical symptoms, fatigue, depression, relation-
ship with others, and frustration) and the overall score
were signiﬁcantly improved at end point compared
with baseline (mean change range: 0.8–1.5 for
domains and 5.4 overall; all P < 0.0001).
Discussion
Fatigue and functional impairment are aspects of
chronic disease that impact patients’ daily lives. These
studies indicate that the effect of treatment for various
condition- or treatment-associated anemia can be cap-
tured by evaluating HRQL outcomes using the LASA,
FACT, and MOS measures; which are designed to
evaluate within-group and between-group differences
in energy/fatigue, functional ability, and overall
HRQL.
Findings from trials of patients with cancer, HIV/
AIDS, and CKD showed clinical and HRQL beneﬁts ofTa
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treatment with epoetin alfa. This ﬁnding is true in both
between-group differences shown in RCTs (comparing
changes over time for epoetin alfa and placebo/SOC)
and within-group changes in single arm studies, where
signiﬁcant improvements in HGB and HRQL/fatigue
were seen as early as 8 weeks in HIV/AIDS patients
and 12–16 weeks in cancer and CKD patients.
This positive relationship is particularly evident
when evaluating fatigue and HGB correction to
approximately 11–12 g/dl as recommended in oncol-
ogy, CKD, and HIV/AIDS clinical practice guidelines
[14–16]. In six of seven evaluations (two cancer, three
HIV, one CKD) where HGB concentrations raised by
at least 2 g/dl from baseline to end point (range 2.2–
2.9 g/dl) and HGB was corrected to at least 11 g/dl in
cancer or CKD and >12 g/dl in HIV/AIDS (range 12.1–
13.0 g/dl), energy scores demonstrated clinically mean-
ingful changes between 5.9 and 27.9 mm (Fig. 2).
Similarly, in ﬁve of seven evaluations, clinically mean-
ingful improvements were seen in LASA activities
scores ranging from 3.1 to 24.5 mm (Fig. 3).
Clinically signiﬁcant improvements were also seen
when using other measures such as the FACT-An
fatigue in cancer patients and the MOS summary
scores in HIV/AIDS patients. Correction of HGB
by increases of at least 2 g/dl were associated with
improvements in FACT-An fatigue scores ranging
from 1.2 to 4.3 points (three of four evaluations) and
in MOS MCS and PCS scores ranging from 5 to 8
points (three of three evaluations). MOS-HIV energy/
fatigue scores were also clinically relevant in three of
three evaluations based on previous work by Wu and
colleagues suggesting that improvements of >7 points
on the energy/fatigue scale are consistent with a clini-
cal change from a symptomatic to an asymptomatic
HIV-infected patient with regard to energy and fatigue
[59].
Across trials and HRQL measures, clinically signiﬁ-
cant improvements were seen in 15 of 16 evaluations
where clinically meaningful changes were deﬁned as
improvements of 6–8% for between-group differences
or within-group changes (Fig. 4). The 6–8% range
value is based on the fact that the minimally important
difference for the LASA scales (8–10 mm), FACT-An
fatigue scale (3 points) corresponds to 6–8% of the
highest possible score for each measure (8–10% and
6%). In 15 of 16 evaluations of tiredness from nine
studies where HGB concentrations were corrected to
guideline levels of at least 11 g/dl in cancer or CKD
and 12 g/dl in HIV/AIDS (range 11.4–13.6 g/dl),
fatigue and energy scores using the FACT, LASA, and
MOS measures demonstrated clinically meaningful
differences or changes between 0.8 and 27.9% (Fig. 4).
In six studies where HGB was corrected to at least
11 g/dl in cancer or CKD and 12 g/dl in HIV/AIDS and
was raised by at least 2 g/dl from baseline to end point
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Figure 2 Changes in hemoglobin (HGB) and Linear Analog Scale Assessment (LASA) energy scores from baseline to end point for HGB corrected to
guideline levels.1,2,3 1Changes of 8 to 10 points on the LASA scales are considered clinically meaningful. 2Changes of 2 g/dl in HGB are considered clinically
meaningful. 3HGB corrected to at least 11 g/dl in cancer or chronic kidney disease (CKD) and >12 g/dl in HIV/AIDS. MID, minimally important difference;
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(range 2.2–2.9 g/dl), clinically meaningful differences
or changes in fatigue and energy scores ranged from
8.7% to 27.9%.
These ﬁndings are consistent with those found in
previous cancer trials demonstrating the positive asso-
ciation between response to therapy (e.g., deﬁned as
an improvement in HGB of 2 g/dl) and improved
HRQL outcomes. In these trials, responders to therapy
had signiﬁcantly better outcomes than nonresponders
based on the FACT-An, which includes items assessing
energy, ability to do activities, and fatigue [46,75,76].
This relationship was signiﬁcant even after controlling
for clinical and demographic variables such as age,
sex, baseline fatigue, tumor or malignancy type, and
history of chemotherapy [75]. In addition, overall
HRQL (based on LASA) improved with incremental
changes in HGB (1–2 g/dl) until levels of 12 g/dl were
reached [77]. Subsequent incremental increases in
HGB resulted in smaller HRQL gains until levels of
14 g/dl were reached [77].
Findings for this literature review are limited by the
data available in the published literature from January
1993 to September 2005. For example, there is vari-
ability across disorders in the dating of published
studies, where 0 of nine cancer studies, two of six HIV
studies [54,57], and two of three CKD studies [63,64]
were published before 2000. This variability makes it
difﬁcult to compare treatment with epoetin alfa against
SOC and points to the need for ongoing research to
ensure that the relative effects of treatment are main-
tained as standards change. In addition, the type and
quality of data available limited our ability to summa-
rize ﬁndings consistently across trials and disorders.
For example, only two of six HIV studies [53,58]
reported HGB levels and only three of six HIV studies
[53,57,58] reported HRQL ﬁndings. Studies of CKD
reported signiﬁcance levels for HRQL ﬁndings without
providing mean values. Again, the variability in data
highlights the need to include all available data, both
clinical and HRQL, in publications of trial ﬁndings to
gain a comprehensive understanding of the impact of
treatment. In addition, lack of uniform HRQL assess-
ment across trials limited our ability to compare ﬁnd-
ings. This was particularly true for studies of HIV/
AIDS and predialysis CKD, where various instruments
were used to evaluate HRQL.
Findings also may be limited by the variation in
the deﬁnition of anemia for study inclusion (range
10.5 g/dl to 9–14 g/dl), where the interpretation of
improvements in HGB and consequent impact on
HRQL after treatment may be difﬁcult. For example,
in all four cancer trials where there were clinically
relevant changes in HGB (i.e., increases of at least
2 g/dl) for patients treated with epoetin alfa (of the
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eight trials reporting HGB changes) [25,29,30,32],
HGB levels at baseline were approximately 10 g/dl
and improved to at least 12 g/dl. Clinically relevant
changes in HRQL were seen in three of these four
trials. In two other cancer trials [41,42], baseline HGB
levels were higher (approximately 13 and 11 g/dl) with
smaller improvements in HGB (0.8 and 1.6 g/dl).
Clinically relevant HRQL changes were seen in one of
the two trials. Although the change in HGB for this
trial was not clinically relevant, it may have been suf-
ﬁcient to improve clinical status and HRQL outcomes.
These ﬁndings may reﬂect the differential beneﬁt of
epoetin alfa use in patients with HGB levels above the
target level of 12.0 g/dl. The fact that not all cancer
trials reported changes in HGB further highlights the
need to include all relevant clinical data in reports of
HRQL ﬁndings.
Although ﬁndings from cancer trials are the stron-
gest, some of the studies were limited by their small
sample size, where tests for statistical signiﬁcance were
not performed because of lack of power or nonran-
domized study design. In HIV/AIDS or CKD where the
majority of trials were nonrandomized and/or open-
label, ﬁndings may be limited by measurement bias
(e.g., reporting bias) inherent to the study design.
In summary, the data available in the published
literature suggest that treatment of anemia in various
conditions (i.e., cancer, HIV/AIDS, and CKD) has a
signiﬁcant impact on HRQL, particularly fatigue, and
that this impact is both statistically and clinically
signiﬁcant.
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